Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
MoonLake Immunotherapeutics (MLTX) has provided an update.
MoonLake Immunotherapeutics has announced the backing of both the FDA and EMA for advancing their Phase 3 program for Nanobody® sonelokimab in treating psoriatic arthritis, signaling a major step forward. This approval sets the stage for the IZAR trial, aiming to enroll 1,500 patients to substantiate a future biologics license. While the news is promising, it’s important to note that these forward-looking statements are subject to various uncertainties, underscoring the inherent risks of drug development and the volatility that can accompany such announcements in the financial markets.
Learn more about MLTX stock on TipRanks’ Stock Analysis page.
